Biogen Inc agreed to pay $900 million to settle allegations about improper physician payments; the American Cancer Society warns that fertility preservation for patients with cancer is at risk after the overturn of Roe v Wade; the Supreme Court will hear a case about Medicaid recipients’ ability to sue their providers.
Biogen Inc has agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid through kickback payments to physicians for prescribing Biogen drugs. This payment resolves a lawsuit that was filed by a former Biogen employee under the False Claims Act. The lawsuit alleged that Biogen paid physicians kickbacks to entice them to prescribe Biogen’s drugs for multiple sclerosis from January 1, 2009, to March 18, 2014. Biogen will be paying the United States government $843,805,187 and 15 states will receive $56,194,813.
The American Cancer Society warned that fertility preservation options for patients with cancer could be at risk in a post–Roe v Wade world. Gene testing and storage and disposal of embryos could be areas where restrictions are imposed in the future, according to the American Cancer Society. Researchers found that of more than 120,000 patients aged 15 to 44 years who were diagnosed with cancer in 2018, 68% of them needed fertility preservation services. Of those, there were 32,000 patients who lived in the 22 states where abortion bans exist or are expected to be passed.
The Supreme Court plans to hear a case on Medicaid recipients’ ability to sue providers, which could potentially open the door to further rollback of the program’s benefits. The decision will determine whether tens of millions of beneficiaries of public welfare programs can sue their providers if their essential needs like health care and food are at risk, which would be more efficient than waiting on the federal government. Conservative judges and lawyers have argued that health care providers or individuals should not be able to sue in cases of Medicaid coverage. Arguments in the current case, Health and Hospital Corp v Talevski, are set to start on November 8.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More